Vyriad specializes in the development of engineered virus platforms aimed at delivering targeted genetic therapies, including in vivo gene therapies, genome editing, and oncolytic virotherapies. Their approach leverages the unique properties of viruses, particularly the vesicular stomatitis virus (VSV) and measles virus, to create stable and efficient viral vectors that can effectively target and infect cancer cells. The company's oncolytic measles virus platform is designed to not only kill tumor cells directly but also to stimulate the patient's immune response against cancer. This is achieved through a fusogenic mechanism that allows the virus to spread between neighboring cancer cells, creating multinucleated cells that are non-viable, thereby enhancing the overall therapeutic effect.

In addition to their innovative viral platforms, Vyriad emphasizes a collaborative and cross-functional approach to therapeutic development. Their clinical programs involve partnerships with leading pharmaceutical companies and medical institutions, allowing them to conduct extensive clinical trials across various cancer indications. The company is currently advancing multiple oncolytic virotherapies, including their lead asset, Measles-NIS, which is engineered for precision targeting of cancer cells and includes features for monitoring virus delivery and infection. Through these efforts, Vyriad aims to deliver potentially curative therapies to patients while continuously refining their methodologies based on clinical outcomes and patient responses.

United States

Vyriad is a biotechnology company that develops targeted genetic therapies using engineered viruses and viral vectors for oncolytic virotherapy and gene editing applications.

Vyriad

Company Details